Chloral Hydrate Alters Brain Activation Induced by Methamphetamine-Associated Cue and Prevents Relapse.
addiction
brain activation
chloral hydrate (CH)
cue-induced relapse
methamphetamine
Journal
Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
05
2022
accepted:
10
06
2022
entrez:
28
7
2022
pubmed:
29
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Methamphetamine is a highly addictive drug and its abuse leads to serious health and social problems. Until now, no effective medications are yet available for the treatment of methamphetamine addiction. Our study reveals that chloral hydrate, a clinical sedative drug, suppresses the seeking desire for methamphetamine. After 5 days of continuous administration (subanesthetic dose 50 mg/kg and 100 mg/kg), methamphetamine-seeking behavior of rats was inhibited in the condition place preference and intravenous self-administration tests. Furthermore, chloral hydrate treatment robustly suppressed cue-induced methamphetamine relapse. The whole brain c-fos immunostaining revealed that chloral hydrate treatment suppressed neuronal activity in the rhomboid thalamic nucleus (Rh), dorsal endopiriform nucleus (dEn), and claustrum (Cl) while enhanced zona incerta (ZI) activity during cue-induced methamphetamine relapse. Therefore, chloral hydrate could remodel neural network activity and serve as a potential medicine to treat methamphetamine addiction.
Identifiants
pubmed: 35898698
doi: 10.3389/fnmol.2022.934167
pmc: PMC9309691
doi:
Types de publication
Journal Article
Langues
eng
Pagination
934167Informations de copyright
Copyright © 2022 Jiang, Xu, Zhong, Wu, He, Xu and Zhu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Comp Neurol. 2017 Apr 15;525(6):1363-1380
pubmed: 26860547
J Pharmacol Exp Ther. 2006 Sep;318(3):1137-45
pubmed: 16740620
Br J Ophthalmol. 2017 Oct;101(10):1423-1430
pubmed: 28242616
Cochrane Database Syst Rev. 2021 Aug 16;8:CD011786
pubmed: 34397100
J Neurosci. 2009 Nov 25;29(47):14734-40
pubmed: 19940168
Brain Res. 1992 Jul 3;584(1-2):213-8
pubmed: 1381265
Neuroscience. 2004;127(1):233-42
pubmed: 15219685
Prog Neurobiol. 2005 Apr;75(6):406-33
pubmed: 15955613
Neurosci Lett. 2003 May 29;343(1):9-12
pubmed: 12749985
J Comp Neurol. 2019 Feb 1;527(2):476-499
pubmed: 30225888
J Comp Neurol. 2008 Jun 1;508(4):648-62
pubmed: 18383504
Life Sci. 2000 Oct 27;67(23):2883-7
pubmed: 11106003
J Neurosci. 2010 Aug 25;30(34):11346-55
pubmed: 20739555
Neuropsychopharmacology. 2021 Jan;46(2):297-304
pubmed: 32450570
Neuropsychopharmacology. 2021 Jan;46(2):305-315
pubmed: 32682325
J Pediatr Ophthalmol Strabismus. 2014 May-Jun;51(3):154-9
pubmed: 24627951
Neuropsychol Rev. 2007 Sep;17(3):275-97
pubmed: 17694436
Hippocampus. 2011 Aug;21(8):815-26
pubmed: 20572196
Brain Res Bull. 2007 Mar 30;71(6):601-9
pubmed: 17292803
J Neurosci. 2019 Dec 11;39(50):10071-10080
pubmed: 31704786
Acta Paediatr. 2010 Feb;99(2):209-14
pubmed: 19839963
Expert Rev Clin Pharmacol. 2017 Mar;10(3):305-314
pubmed: 27927042